|
Shilpa Medicare launched the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name AXISHIL.
AXISHIL is available as 1 mg & 5 mg tablets in pack of 14's tablets in one
bottle.
AXISHIL is used to treat patients suffering from Advanced Renal Cell
Carcinoma (RCC).
This novel targeted therapy attacks cancer cells without damaging normal
cells, thus causing fewer side effects. There has been a_ significant
improvement in survival rates in patients with advanced renal cancer due to advent of this novel targeted therapy.
Currently the monthly therapy cost of innovator is approximately Rs 1.66 lakh and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs 14940/-.
drastically to Rs. 14940/-.
|